Dong-A Pharmaceutical동아제약

Dong-A Pharmaceutical's trailing profit is steady and its valuation looks low, but the share price is down 18% over the past year.

Dong-A Pharmaceutical is a holding company with consumer health, pharmaceutical, logistics and packaging businesses. Over the trailing twelve months to H1 2026 it reported revenue of ₩1.52T, operating income of ₩107B and net income of ₩85B, with a 5.6% net margin. The shares closed at ₩89,800 on 2026-10-23, about 40% below the 52-week high of ₩125,500.

What stands out

• Trailing revenue of ₩1.52T is above the 2025 full-year figure of ₩1.43T, and 2025 revenue grew 7.2% on 2024.
• Operating margin improved to 7.1% on a trailing basis from 6.8% in 2025, though net income in 2025 (₩91B) was higher than the trailing ₩85B.
• Valuation metrics are low: P/E of 7.1, P/B of 0.5 and a 1.9% dividend yield, compared with the company's own fair value model range of ₩74,061 to ₩155,529 (base ₩111,092).
• Borrowings of ₩570B exceed cash of ₩184B, and liabilities are 82.9% of equity; trailing free cash flow was ₩192B.
• Foreign ownership rose to 17.4% from 16% sixty days earlier, while retail and institutional investors were net sellers over the last 20 days.

What to watch

• The advance earnings notice filed on 2026-10-22 signals upcoming results; the full figures are not yet in the data.
• A major sales or supply contract was filed on 2026-10-16; its size and terms are not stated in the data.
• Largest shareholder holding changes and a run of insider shareholding reports were filed on 2026-10-08, and their meaning is not explained in the data.